134-47-4
![134-47-4 结构式](/CAS/GIF/134-47-4.gif)
基本信息
猩红酸
7,7-(羰基二亚氨基)二(4-羟基-2-萘磺酸)
6,6'-ureylene-bis(1-naphthol-3-sulfonic acid)
7,7'-(Carbonyldiimino)bis[4-hydroxy-2-naphthalenesulfonic acid]
phosgenated
N,N'-bis(4-hydroxy-2-sulfonaphthalene-7-yl)urea
7,7'-Ureylenebis(4-hydroxy-2-naphthalenesulfonic acid)
N,N'-Bis[6-(1-naphthol-3-sulfonic acid)]urea
2-Naphthalenesulfonic acid, 7,7-(carbonyldiimino)bis4-hydroxy-
J ACID UREA, FREE ACID
66UREYLENEBIS1NAPHTHOL3SULPHONICACIDDISODIUMSALT
7,7'-(carbonyldiimino)bis[4-hydroxy-2-naphthalenesulfonic aci
6,6'-ureylenbis-1-naphthol-3-sulfonic acid
7,7'-(Carbonylbisimino)bis(4-hydroxynaphthalene-2-sulfonic acid)
物理化学性质
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/08/19 | HY-18962A | 猩红酸 AMI-1 free acid | 134-47-4 | 5mg | 187元 |
2024/08/19 | HY-18962A | 猩红酸 AMI-1 free acid | 134-47-4 | 10mg | 300元 |
2024/08/19 | HY-18962A | 猩红酸 AMI-1 free acid | 134-47-4 | 10mM * 1mLin DMSO | 330元 |
常见问题列表
Target | Value |
HMT
() | |
human PRMT1
() | |
yeast Hmt1p
(Cell-free assay) | 3.0 μM |
AMI-1 free acid can inhibit the in vitro methylation reactions performed by all five recombinantly active PRMTs (PRMT1, -3, -4, and -6 and Hmt1p).
AMI-1 free acid not only inhibits type I PRMTs (PRMT1, 3, 4 and 6) but also type II PRMT5.
AMI-1 free acid specifically inhibits arginine, but not lysine, methyltransferase activity in vitro and does not compete for the AdoMet binding site.
AMI-1 free acid inhibits methylation of GFP-Npl3 and cellular proteins.
AMI-1 free acid (0.6-2.4 mM; 48-96 hours) inhibits the cell viability of sarcoma in S180 and U2OS cells in a time-dependent and dose-dependent manner in vitro.
AMI-1 free acid (1.2-2.4 mM; 48-72 hours) reduces S180 cell viability through the induction of cell apoptosis.
Cell Viability Assay
Cell Line: | S180 cells, U2OS cells |
Concentration: | 0.6 mM, 1.2 mM, 2.4 mM |
Incubation Time: | 48 hours, 72 hours, 96 hours |
Result: | Inhibited the cell viability. |
Apoptosis Analysis
Cell Line: | S180 cells |
Concentration: | 1.2 mM, 2.4 mM |
Incubation Time: | 48 hours, 72 hours |
Result: | Increased the percentages of cells undergoing apoptosis. |
AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) inhibits S180 viability in vivo.
AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) downregulates PRMT5 but does not regulate the expression of PRMT7 in a tumor xenograft model.
AMI-1 free acid (0.5 mg; intratumorally; daily; for 7 days) decreases the levels of H4R3me2s and H3R8me2s in a tumor xenograft model.
Animal Model: | 6-7 weeks old male Kunming mice (18-22 g), with S180 cells xenograft |
Dosage: | 0.5 mg |
Administration: | Intratumorally, daily, for 7 days |
Result: | Decreased tumor weight. |